$PROF

Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) will report its Q2 2026 financial results after market close on Aug. 6, 2026, and hold a conference call at 4:30 p.m. ET to discuss results and business updates, according to the company. The release also describes its iMRI platforms TULSA-PRO and Sonalleve and related regulatory clearances.

Original reporting
Published Jul 16, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow — source image
Decision brief

The 30-second read

$PROFNeutralMed
01

Why it matters

The primary tradable element is the scheduled Q2 2026 results release after the close on Aug. 6, followed by a 4:30 p.m. ET conference call.

02

Market read

This is a forward-looking earnings-event scheduling update that can inform options and pre-earnings positioning, but it contains no financial metrics or guidance.

03

What to watch

Volatility may be driven more by any subsequent 8-K/press release details (revenue, margins, procedure volumes, guidance) than by the scheduled call time, which is not itself predictive.

Relevance 5/10Novelty 5/10Timing: after-market-close earnings release scheduled for Aug. 6, 2026

Background

Profound is a commercial-stage medical device company focused on interventional MRI procedures (TULSA-PRO and Sonalleve).

Company-level read

Ticker impact

$PROFNeutralMedium confidence
Context

Profound Medical will release Q2 2026 financial results after the close on Aug. 6 and hold a 4:30 p.m. ET conference call.

Expected impact

Likely modest pre-event positioning and post-release volatility; direction depends on Q2 results and guidance, which are not provided here.

Evidence & confidence

The article discloses only the timing of the upcoming results and call, with no numbers, guidance, or operational updates.

Market effects

Could increase near-term attention on commercial-stage interventional MRI device names ahead of results season, but no sector datapoints are disclosed.

Limited, since the disclosure is company-specific and not tied to a macro/regional policy change.

Low, despite mentioning global clearances, because no new regulatory or commercial expansion facts are provided.

Counterpoint

Because the release date is already the main disclosed item, traders may treat this as largely priced-in and focus on what management says on the call rather than the calendar itself.

Key entities

  • Profound Medical Corp.

    NASDAQ-listed medical device company announcing its Q2 2026 results date and conference call details.

Related articles

$PROFMed

Profound Medical Corp. (PROF): Results of Operations and Financial Condition

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early

$ATLCMed

Atlanticus (ATLC) Q2 2026 Earnings Call Transcript

Atlanticus (ATLC) reported Q2 2026 net income attributable to common shareholders of $47.4 million, up 67% year over year, or $2.50 per diluted share. Total operating revenue and other income rose to $744.3 million (+89%). The company said managed receivables grew to $6.9 billion (+126% YoY), helped by Mercury integration, and it maintained a 20% return on equity target.

$WWWHighAI 9/10

Wolverine World Wide Q2 Earnings Call Highlights

Wolverine World Wide (NYSE:WWW) reported Q2 call highlights, including brand performance across Merrell, Saucony, Sweaty Betty and Work Group. The company raised fiscal 2026 revenue outlook to $1.98B-$2.0B, gross margin to ~46.9%, adjusted diluted EPS to $1.55-$1.65, and operating free cash flow to $115M-$130M, citing inventory and margin actions despite tariff headwinds.

$STNMed

Stantec Q2 Earnings Call Highlights

Stantec (NYSE:STN) reported Q2 organic growth near 12%, with water up over 20% and energy and resources supported by projects in Chile and Peru. U.S. net revenue rose about 13% on Page acquisition, while U.S. organic growth was flat. Backlog hit a record CAD 9.2B. 2026 outlook: net revenue growth 8.5% to 11.5%, adjusted EBITDA margin 17.8% to 18.3%.

$YSSMed

York Space Systems Q2 Earnings Call Highlights

York Space Systems (NYSE:YSS) reported Q2 gross margin of 24% versus 11% a year earlier, with gross profit rising to $22.2 million. Backlog was $592 million at June 30. The company guided for mid-20% gross margins in 2026 and said supply-chain delays and removed revenue expectations offset each other. Adjusted EBITDA loss widened to $9.5 million.

$TSSIMed

TSS Q2 Earnings Call Highlights

TSS (NASDAQ:TSSI) reported Q2 results on an earnings call. Systems integration remained the main growth driver, with gross profit up 11% to $8.0M and blended gross margin rising to 22.8%. Adjusted EBITDA increased 12% to $4.5M. TSS plans a ~$17M expansion for NVIDIA’s Vera Rubin platform, with incremental revenue expected to start in Q3 and mainly impact Q4.